Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15032581 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer
Conditions: Sarcoma;   Wilm's Tumor;   Lymphoma;   Neuroblastoma
Intervention: Drug: Ipilimumab

Indicates status has not been verified in more than two years